https://news.medxy.ai/zh/bridging-als-trust-gap/Medxy AIzh2026-09-16T10:10:19-07:00弥合 ALS 临床试验的可信度鸿沟：迈向更严谨、更审慎的治疗开发 https://news.medxy.ai/ja/74685-2/Medxy AIja2026-09-16T10:10:00-07:00ALS臨床試験における信頼性のギャップを埋める：より厳密かつ慎重な治療法開発に向けて https://news.medxy.ai/vi/als-test-reliability-gap/Medxy AIvi2026-09-16T10:09:40-07:00Lấp đầy khoảng cách về độ tin cậy trong thử nghiệm ALS: Hướng tới tính nghiêm ngặt và hoài nghi lớn hơn trong phát triển điều trị https://news.medxy.ai/zh/carotid-stenting-benefits/Medxy AIzh2026-09-16T10:08:30-07:00CREST-2揭示：颈动脉支架置入术可作为强化药物治疗的有效辅助手段，降低卒中风险 https://news.medxy.ai/ja/stroke-prevention-options/Medxy AIja2026-09-16T10:08:13-07:00脳卒中予防の新たな有力選択肢：CREST-2が示した頸動脈ステント留置術と集中的内科治療の意義 https://news.medxy.ai/vi/carotid-stent-prevention/Medxy AIvi2026-09-16T10:07:54-07:00Đặt stent động mạch cảnh nổi lên như một biện pháp bổ trợ đã được chứng minh trong phòng ngừa đột quỵ: Góc nhìn từ CREST-2 https://news.medxy.ai/carotid-artery-stenting-emerges-as-a-proven-adjunct-to-intensive-medical-therapy-in-stroke-prevention-insights-from-crest-2/Medxy AIen2026-09-16T10:07:36-07:00Carotid Artery Stenting Emerges as a Proven Adjunct to Intensive Medical Therapy in Stroke Prevention: Insights from CREST-2 https://news.medxy.ai/zh/korsakoff-syndrome/Medxy AIzh2026-09-16T10:06:48-07:00Korsakoff综合征：临床特征、脑影像学发现与死亡风险 https://news.medxy.ai/ja/korsakoff-syndrome-analysis/Medxy AIja2026-09-16T10:06:27-07:00Korsakoff症候群の臨床像・脳画像所見・死亡リスクを大規模コホートで解析 https://news.medxy.ai/vi/74666-2/Medxy AIvi2026-09-16T10:06:02-07:00Hội chứng Korsakoff: Đặc điểm lâm sàng, hình ảnh thần kinh và nguy cơ tử vong https://news.medxy.ai/korsakoff-syndrome-clinical-profiles-brain-imaging-insights-and-mortality-risks-in-a-large-cohort/Medxy AIen2026-09-16T10:05:41-07:00Korsakoff Syndrome: Clinical Profiles, Brain Imaging Insights, and Mortality Risks in a Large Cohort https://news.medxy.ai/zh/ivig-prednisone-imyopathy/Medxy AIzh2026-09-16T10:04:35-07:00IVIG联合泼尼松可显著加速新诊断特发性炎性肌病康复：随机临床试验解读 https://news.medxy.ai/ja/ivig-prednisone-efficacy/Medxy AIja2026-09-16T10:04:17-07:00新規診断の特発性炎症性筋疾患に対するIVIG併用プレドニゾンの有効性：ランダム化臨床試験からの知見 https://news.medxy.ai/vi/ivig-prednisone-treatment/Medxy AIvi2026-09-16T10:03:56-07:00IVIG phối hợp prednisone giúp phục hồi tốt hơn ở bệnh viêm cơ viêm vô căn mới chẩn đoán: Góc nhìn từ thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/ivig-plus-prednisone-enhances-recovery-in-newly-diagnosed-idiopathic-inflammatory-myopathies-insights-from-a-randomized-clinical-trial/Medxy AIen2026-09-16T10:03:36-07:00IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial https://news.medxy.ai/zh/prediabetes-activity-benefits/Medxy AIzh2026-09-16T10:02:48-07:00前驱糖尿病表型不同，身体活动改善幅度也不同：来自随机对照试验合并分析的启示 https://news.medxy.ai/ja/prediabetes-activity-response/Medxy AIja2026-09-16T10:02:25-07:00前糖尿病のタイプで異なる身体活動反応：糖尿病予防介入のプール解析から見えた示唆 https://news.medxy.ai/vi/physical-activity-interventions/Medxy AIvi2026-09-16T10:01:57-07:00Đáp ứng hoạt động thể chất khác nhau với các can thiệp giảm nguy cơ đái tháo đường theo kiểu hình tiền đái tháo đường: Bằng chứng từ các thử nghiệm ngẫu nhiên có đối chứng phân tích gộp https://news.medxy.ai/differential-physical-activity-responses-to-diabetes-risk-reduction-interventions-according-to-prediabetes-phenotype-insights-from-pooled-randomized-controlled-trials/Medxy AIen2026-09-16T10:01:34-07:00Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled Trials https://news.medxy.ai/zh/sweden-pregnancy-diabetes/Medxy AIzh2026-09-16T10:00:30-07:00瑞典全国队列研究揭示妊娠期糖尿病中的社会不平等 https://news.medxy.ai/ja/swedish-pregnancy-diabetes/Medxy AIja2026-09-16T10:00:11-07:00スウェーデン全国コホートでみる妊娠糖尿病の社会的不平等 https://news.medxy.ai/vi/social-inequality-gestational-diabetes/Medxy AIvi2026-09-16T09:59:48-07:00Bất bình đẳng xã hội trong đái tháo đường thai kỳ: góc nhìn từ một nghiên cứu đoàn hệ toàn quốc tại Thụy Điển https://news.medxy.ai/social-inequalities-in-gestational-diabetes-insights-from-a-nationwide-swedish-cohort-study/Medxy AIen2026-09-16T09:59:24-07:00Social Inequalities in Gestational Diabetes: Insights from a Nationwide Swedish Cohort Study https://news.medxy.ai/zh/oxytocin-obesity-thyroid/Medxy AIzh2026-09-16T09:58:39-07:00催产素如何影响肥胖中的甲状腺功能与心理健康：一项8周临床试验的启示 https://news.medxy.ai/ja/oxytocin-obesity-effects/Medxy AIja2026-09-16T09:58:20-07:00肥満におけるオキシトシンの甲状腺機能・メンタルヘルスへの影響：8週間臨床試験からの知見 https://news.medxy.ai/vi/oxytocin-thyroid-mental-health/Medxy AIvi2026-09-16T09:57:58-07:00Oxytocin trong điều hòa chức năng tuyến giáp và sức khỏe tâm thần ở béo phì: Góc nhìn từ thử nghiệm lâm sàng 8 tuần https://news.medxy.ai/oxytocins-role-in-modulating-thyroid-function-and-mental-health-in-obesity-insights-from-an-8-week-clinical-trial/Medxy AIen2026-09-16T09:57:39-07:00Oxytocin’s Role in Modulating Thyroid Function and Mental Health in Obesity: Insights from an 8-Week Clinical Trial https://news.medxy.ai/ja/ai-mobile-health-impact/Medxy AIja2026-09-16T05:17:15-07:00AI搭載ゲーム化モバイルヘルスアプリが血圧管理に与える影響：マッチド患者コホート研究 https://news.medxy.ai/vi/ai-health-apps/Medxy AIvi2026-09-16T05:16:59-07:00Ứng dụng di động y tế có AI và trò chơi hóa cải thiện kiểm soát huyết áp trong một đoàn hệ bệnh nhân ghép cặp https://news.medxy.ai/impact-of-an-ai-powered-gamified-mobile-health-application-on-blood-pressure-control-in-a-matched-patient-cohort/Medxy AIen2026-09-16T05:16:45-07:00Impact of an AI-Powered Gamified Mobile Health Application on Blood Pressure Control in a Matched Patient Cohort https://news.medxy.ai/zh/community-health-empowerment/Medxy AIzh2026-09-16T05:16:12-07:00社区健康中心的赋能技术：突破障碍，回应照护管理患者的健康社会决定因素 https://news.medxy.ai/ja/74299-2/Medxy AIja2026-09-16T05:15:56-07:00地域保健センターにおけるエンパワーメント技術：障壁を克服し、ケアマネジメント対象患者の健康の社会的決定要因に対応する https://news.medxy.ai/vi/healthcare-support-technology/Medxy AIvi2026-09-16T05:15:39-07:00Công nghệ hỗ trợ tại trung tâm y tế cộng đồng: Vượt rào cản để giải quyết các yếu tố xã hội quyết định sức khỏe ở bệnh nhân được quản lý chăm sóc https://news.medxy.ai/enabling-technologies-in-community-health-centers-overcoming-barriers-to-address-social-determinants-of-health-in-care-managed-patients/Medxy AIen2026-09-16T05:15:23-07:00Enabling Technologies in Community Health Centers: Overcoming Barriers to Address Social Determinants of Health in Care-Managed Patients https://news.medxy.ai/zh/74294-2/Medxy AIzh2026-09-16T05:14:52-07:00何时开始美沙酮带药治疗：证据综合与对阿片类药物使用障碍管理的临床启示 https://news.medxy.ai/ja/methadone-home-use/Medxy AIja2026-09-16T05:14:32-07:00メサドン持ち帰り投与はいつ始めるべきか：エビデンス統合とオピオイド使用障害管理への臨床的示唆 https://news.medxy.ai/vi/methadone-treatment-start/Medxy AIvi2026-09-16T05:14:10-07:00Thời điểm khởi đầu methadone mang về nhà: Tổng hợp bằng chứng và hàm ý lâm sàng trong quản lý rối loạn sử dụng opioid https://news.medxy.ai/timing-of-initiation-of-methadone-take-home-dosing-evidence-synthesis-and-clinical-implications-for-opioid-use-disorder-management/Medxy AIen2026-09-16T05:13:50-07:00Timing of Initiation of Methadone Take-Home Dosing: Evidence Synthesis and Clinical Implications for Opioid Use Disorder Management https://news.medxy.ai/mindfulness-group-visits-a-new-approach-to-chronic-low-back-pain-relief/Medxy AIen2026-09-16T05:13:04-07:00Mindfulness Group Visits: A New Approach to Chronic Low Back Pain Relief https://news.medxy.ai/zh/digoxin-cardiovascular-outcomes/Medxy AIzh2026-09-16T05:12:27-07:00洋地黄苷对HFmrEF与HFrEF患者心血管结局的影响：证据综合分析 https://news.medxy.ai/ja/hfmref-hfrer-digitalis-effects/Medxy AIja2026-09-16T05:12:11-07:00HFmrEF・HFrEFにおけるDigitalis glycosidesの心血管転帰への影響：包括的エビデンスの統合 https://news.medxy.ai/vi/digitalis-glycosides-heart-failure/Medxy AIvi2026-09-16T05:11:54-07:00Digitalis glycosides và tác động lên kết cục tim mạch ở HFmrEF và HFrEF: Tổng hợp bằng chứng toàn diện https://news.medxy.ai/impact-of-digitalis-glycosides-on-cardiovascular-outcomes-in-hfmref-and-hfref-a-comprehensive-evidence-synthesis/Medxy AIen2026-09-16T05:11:38-07:00Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence Synthesis https://news.medxy.ai/zh/atg-vs-alemtuzumab-aml/Medxy AIzh2026-09-16T05:09:43-07:00ATG 与 alemtuzumab 在 AML 同种异体移植 GvHD 预防中的比较：来自 EBMT 登记研究的启示 https://news.medxy.ai/ja/aml-gvhd-prevention/Medxy AIja2026-09-16T05:09:29-07:00AML同種移植におけるGvHD予防：ATGとalemtuzumabをEBMTレジストリで比較 https://news.medxy.ai/vi/alemtuzumab-gvhd-prevention/Medxy AIvi2026-09-16T05:09:11-07:00ATG hay Alemtuzumab: lựa chọn nào tối ưu để dự phòng GvHD trong ghép allo-HCT cho AML? https://news.medxy.ai/atg-versus-alemtuzumab-for-gvhd-prophylaxis-in-aml-allo-hct-insights-from-the-ebmt-registry/Medxy AIen2026-09-16T05:08:54-07:00ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry https://news.medxy.ai/zh/graft-versus-host-disease-prevention/Medxy AIzh2026-09-16T05:08:20-07:00AML与MDS减低强度配型供者移植后GVHD预防如何优化：PTCy与ATG策略的新启示 https://news.medxy.ai/ja/aml-mds-gvhd-prevention/Medxy AIja2026-09-16T05:08:04-07:00AML・MDSにおける減量強度同種移植後GVHD予防の最適化：PTCyとATG戦略からみた知見 https://news.medxy.ai/vi/gvhd-prophylaxis-optimization/Medxy AIvi2026-09-16T05:07:47-07:00Tối ưu hóa dự phòng GVHD sau ghép từ người cho phù hợp với điều kiện cường độ giảm ở AML và MDS: Góc nhìn từ chiến lược PTCy và ATG https://news.medxy.ai/optimizing-gvhd-prophylaxis-after-reduced-intensity-matched-donor-transplantation-in-aml-and-mds-insights-from-ptcy-and-atg-strategies/Medxy AIen2026-09-16T05:07:30-07:00Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies https://news.medxy.ai/zh/pediatric-lymphoma-variants-2/Medxy AIzh2026-09-16T05:06:52-07:00儿童淋巴瘤易感生殖系变异：对诊断年龄与生存结局的影响 https://news.medxy.ai/ja/pediatric-lymphoma-variants/Medxy AIja2026-09-16T05:06:34-07:00小児リンパ腫の発症年齢と予後を左右する生殖細胞系列バリアント https://news.medxy.ai/vi/lymphoma-risk-variants/Medxy AIvi2026-09-16T05:06:16-07:00Biến thể dòng mầm làm tăng nguy cơ lymphoma: tác động lên tuổi chẩn đoán và tiên lượng ở bệnh nhi https://news.medxy.ai/germline-lymphoma-predisposing-variants-influence-on-age-at-diagnosis-and-survival-outcomes-in-pediatric-patients/Medxy AIen2026-09-16T05:05:59-07:00Germline Lymphoma-Predisposing Variants: Influence on Age at Diagnosis and Survival Outcomes in Pediatric Patients https://news.medxy.ai/zh/chop-vs-choep-epoch-2/Medxy AIzh2026-09-16T05:05:19-07:00侵袭性成人T细胞白血病/淋巴瘤中CHOP与CHOEP/EPOCH方案比较：来自国际队列研究的启示 https://news.medxy.ai/ja/adult-t-cell-leukemia-treatment/Medxy AIja2026-09-16T05:05:04-07:00侵襲性成人T細胞白血病／リンパ腫におけるCHOPとCHOEP/EPOCHの比較：国際コホート研究からの知見 https://news.medxy.ai/vi/chop-vs-choep-epoch/Medxy AIvi2026-09-16T05:04:48-07:00So sánh phác đồ CHOP với CHOEP/EPOCH trong u bạch cầu/u lympho tế bào T ở người lớn tiến triển: phát hiện từ một nghiên cứu đoàn hệ quốc tế https://news.medxy.ai/comparing-chop-and-choep-epoch-regimens-in-aggressive-adult-t-cell-leukemia-lymphoma-insights-from-an-international-cohort-study/Medxy AIen2026-09-16T05:04:29-07:00Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study https://news.medxy.ai/zh/cohesin-mutation-role/Medxy AIzh2026-09-16T05:03:52-07:00解开cohesin突变在HLA II类下调与唐氏综合征白血病进展中的作用 https://news.medxy.ai/ja/74214-2/Medxy AIja2026-09-16T05:03:35-07:00ダウン症における白血病の進行およびHLAクラスIIの発現低下におけるコヒーシン変異の役割の解明 https://news.medxy.ai/vi/cohesin-mutation-leukemia/Medxy AIvi2026-09-16T05:03:16-07:00Làm sáng tỏ vai trò của đột biến cohesin trong giảm điều hòa HLA lớp II và tiến triển bệnh bạch cầu ở hội chứng Down https://news.medxy.ai/unraveling-the-role-of-cohesin-mutations-in-hla-class-ii-downregulation-and-leukemia-progression-in-down-syndrome/Medxy AIen2026-09-16T05:02:58-07:00Unraveling the Role of Cohesin Mutations in HLA-Class II Downregulation and Leukemia Progression in Down Syndrome https://news.medxy.ai/ja/tisagenlecleucel-all/Medxy AIja2026-09-16T05:02:21-07:00移植後再発の若年ALL患者におけるティサゲンレクルセル：欧州リアルワールドデータが示す転帰決定因子 https://news.medxy.ai/vi/tisagenlecleucel-relapse-leukemia/Medxy AIvi2026-09-16T05:02:03-07:00Tisagenlecleucel trong tái phát sau ghép ở bệnh nhân bạch cầu lympho cấp trẻ tuổi: các yếu tố quyết định kết cục từ dữ liệu thực tế châu Âu https://news.medxy.ai/tisagenlecleucel-for-post-transplant-relapse-in-young-acute-lymphoblastic-leukemia-patients-european-real-world-determinants-of-outcome/Medxy AIen2026-09-16T05:01:45-07:00Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome https://news.medxy.ai/zh/fap-1-deficiency-2/Medxy AIzh2026-09-16T05:01:10-07:00FAP-1缺乏：连接巨核细胞成熟障碍、血小板功能异常与类骨髓纤维化疾病的新机制 https://news.medxy.ai/ja/fap-1-deficiency/Medxy AIja2026-09-16T05:00:52-07:00FAP-1欠損が結ぶ新たな病態連関：巨核球成熟不全、血小板機能障害、骨髄線維症様病態 https://news.medxy.ai/vi/fap-1-deficiency-mekakaryocyte/Medxy AIvi2026-09-16T05:00:34-07:00Thiếu hụt FAP-1: Mối liên kết cơ chế mới với trưởng thành megakaryocyte suy giảm, rối loạn chức năng tiểu cầu và bệnh cảnh giống myelofibrosis https://news.medxy.ai/fap-1-deficiency-a-novel-mechanistic-link-to-impaired-megakaryocyte-maturation-platelet-dysfunction-and-myelofibrosis-like-disease/Medxy AIen2026-09-16T05:00:16-07:00FAP-1 Deficiency: A Novel Mechanistic Link to Impaired Megakaryocyte Maturation, Platelet Dysfunction, and Myelofibrosis-like Disease https://news.medxy.ai/zh/ackr3-cxcr7-thrombosis/Medxy AIzh2026-09-16T04:59:41-07:00靶向 ACKR3/CXCR7：增强血小板抗凝脂质并调控促凝功能，为血栓管理提供新思路 https://news.medxy.ai/ja/ackr3-cxcr7-thrombosis-control/Medxy AIja2026-09-16T04:59:23-07:00ACKR3/CXCR7を標的とした血小板抗凝固性脂質の増強と凝固促進機能の制御：血栓管理への新たな示唆 https://news.medxy.ai/vi/ackr3-cxcr7-thrombosis-2/Medxy AIvi2026-09-16T04:59:04-07:00Nhắm trúng ACKR3/CXCR7: tăng lipid chống đông của tiểu cầu và điều biến chức năng tiền đông máu để kiểm soát huyết khối https://news.medxy.ai/targeting-ackr3-cxcr7-enhances-platelet-anticoagulant-lipids-and-modulates-procoagulant-function-implications-for-thrombosis-management/Medxy AIen2026-09-16T04:58:44-07:00Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Lipids and Modulates Procoagulant Function: Implications for Thrombosis Management https://news.medxy.ai/zh/74182-2/Medxy AIzh2026-09-16T04:58:08-07:00重度哮喘早期启动生物制剂治疗：基于全球真实世界队列提升缓解率与临床转归 https://news.medxy.ai/ja/74181-2/Medxy AIja2026-09-16T04:57:52-07:00重症喘息における生物学的製剤の早期導入：世界的なリアルワールド・コホートに基づく寛解および臨床転帰の向上 https://news.medxy.ai/vi/early-biologic-treatment-asthma/Medxy AIvi2026-09-16T04:57:33-07:00Khởi trị sinh học sớm trong hen phế quản nặng: Nâng cao lui bệnh và cải thiện kết cục lâm sàng từ các đoàn hệ thực tế toàn cầu https://news.medxy.ai/early-biologic-initiation-in-severe-asthma-enhancing-remission-and-clinical-outcomes-from-global-real-world-cohorts/Medxy AIen2026-09-16T04:57:13-07:00Early Biologic Initiation in Severe Asthma: Enhancing Remission and Clinical Outcomes from Global Real-World Cohorts https://news.medxy.ai/zh/icu-palliative-care-2/Medxy AIzh2026-09-16T04:56:23-07:00优化ICU姑息照护：专科临床医师对整合与影响的见解 https://news.medxy.ai/ja/icu-palliative-care/Medxy AIja2026-09-16T04:56:09-07:00ICUにおける緩和ケアをどう高めるか：専門医の視点からみた統合と影響 https://news.medxy.ai/vi/palliative-care-icu/Medxy AIvi2026-09-16T04:55:52-07:00Tối ưu hóa chăm sóc giảm nhẹ trong ICU: Góc nhìn từ các bác sĩ chuyên khoa về tích hợp và tác động https://news.medxy.ai/enhancing-palliative-care-in-the-icu-insights-from-specialist-clinicians-on-integration-and-impact/Medxy AIen2026-09-16T04:55:37-07:00Enhancing Palliative Care in the ICU: Insights From Specialist Clinicians on Integration and Impact https://news.medxy.ai/zh/74168-2/Medxy AIzh2026-09-16T04:55:03-07:00ARDS 患者不联合机械通气的体外膜肺氧合治疗：一项国际队列研究的启示 https://news.medxy.ai/ja/74166-2/Medxy AIja2026-09-16T04:54:46-07:00ARDSにおける人工呼吸管理を併用しない体外式膜型人工肺（ECMO）―国際コホート研究からの知見 https://news.medxy.ai/vi/ecmo-no-ventilation-ards/Medxy AIvi2026-09-16T04:54:29-07:00ECMO không thở máy trong ARDS: Góc nhìn từ một nghiên cứu đoàn hệ quốc tế https://news.medxy.ai/extracorporeal-membrane-oxygenation-without-mechanical-ventilation-in-ards-insights-from-an-international-cohort-study/Medxy AIen2026-09-16T04:54:12-07:00Extracorporeal Membrane Oxygenation without Mechanical Ventilation in ARDS: Insights from an International Cohort Study https://news.medxy.ai/zh/asthma-risk-factors-2/Medxy AIzh2026-09-16T04:53:37-07:00从轻至中度到重度哮喘：NORDSTAR队列中的风险因素与患者特征，以及重度哮喘管理新进展 https://news.medxy.ai/ja/asthma-risk-factors-3/Medxy AIja2026-09-16T04:53:16-07:00軽度〜中等度喘息から重症喘息へ：NORDSTARコホートが示す危険因子・患者プロファイルと重症喘息管理の最新進展 https://news.medxy.ai/vi/asthma-risk-factors/Medxy AIvi2026-09-16T04:52:54-07:00Từ hen phế quản nhẹ đến trung bình sang hen phế quản nặng: yếu tố nguy cơ, hồ sơ bệnh nhân từ đoàn hệ NORDSTAR và tiến bộ trong điều trị hen phế quản nặng https://news.medxy.ai/from-mild-to-moderate-to-severe-asthma-risk-factors-and-patient-profiles-from-the-nordstar-cohort-and-advances-in-severe-asthma-management/Medxy AIen2026-09-16T04:52:33-07:00From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma Management https://news.medxy.ai/zh/74145-2/Medxy AIzh2026-09-16T04:51:41-07:00激光视网膜固定术后需行额外视网膜干预的风险分层：累积临床因素的影响 https://news.medxy.ai/ja/74143-2/Medxy AIja2026-09-16T04:51:28-07:00網膜光凝固術後の追加的な網膜介入を要するリスクの層別化：累積的な臨床因子の影響 https://news.medxy.ai/vi/retinopexy-risk-stratification/Medxy AIvi2026-09-16T04:51:11-07:00Phân tầng nguy cơ can thiệp võng mạc bổ sung sau laser retinopexy: tác động của các yếu tố lâm sàng cộng dồn https://news.medxy.ai/stratifying-risk-for-further-retinal-intervention-after-laser-retinopexy-the-impact-of-cumulative-clinical-factors/Medxy AIen2026-09-15T08:50:56-07:00Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical Factors https://news.medxy.ai/zh/74133-2/Medxy AIzh2026-09-15T08:50:25-07:00微型单视（Mini-monovision）与正视状态下屈光型扩展景深人工晶状体（EDOF IOL）的视觉功能 https://news.medxy.ai/ja/extended-depth-focus-iol/Medxy AIja2026-09-15T08:50:04-07:00ミニモノビジョンと正視でみる屈折型拡張焦点深度IOLの視機能：包括的レビュー https://news.medxy.ai/vi/74128-2/Medxy AIvi2026-09-15T08:49:41-07:00Chức năng thị giác của thủy tinh thể nhân tạo (IOL) khúc xạ mở rộng độ sâu tiêu cự khi sử dụng phương pháp Mini-monovision và trạng thái chính thị https://news.medxy.ai/visual-performance-of-a-refractive-extended-depth-of-field-intraocular-lens-in-monovision-and-emmetropic-settings-a-comprehensive-review/Medxy AIen2026-09-15T08:49:20-07:00Visual Performance of a Refractive Extended Depth of Field Intraocular Lens in Monovision and Emmetropic Settings: A Comprehensive Review https://news.medxy.ai/zh/parotidectomy-botox/Medxy AIzh2026-09-15T08:48:29-07:00腮腺切除术中注射A型肉毒毒素：减少术后唾液囊肿的回顾性队列分析 https://news.medxy.ai/ja/botulinum-toxin-salivary-cyst/Medxy AIja2026-09-15T08:48:13-07:00耳下腺摘出術後の唾液瘤予防を目指した術中ボツリヌス毒素投与：後ろ向きコホート解析 https://news.medxy.ai/vi/botulinum-toxin-sialocele/Medxy AIvi2026-09-15T08:47:54-07:00Tiêm độc tố botulinum trong mổ để giảm sialocele sau phẫu thuật cắt tuyến mang tai: Phân tích đoàn hệ hồi cứu https://news.medxy.ai/intraoperative-botulinum-toxin-injection-to-reduce-postoperative-sialocele-after-parotidectomy-a-retrospective-cohort-analysis/Medxy AIen2026-09-15T08:47:35-07:00Intraoperative Botulinum Toxin Injection to Reduce Postoperative Sialocele After Parotidectomy: A Retrospective Cohort Analysis https://news.medxy.ai/zh/female-throat-cancer/Medxy AIzh2026-09-15T08:46:56-07:00女性喉癌治疗结局多中心回顾性分析 https://news.medxy.ai/ja/74115-2/Medxy AIja2026-09-15T08:46:42-07:00女性の喉頭癌治療成績に関する多施設共同後ろ向き解析 https://news.medxy.ai/vi/laryngeal-cancer-treatment/Medxy AIvi2026-09-15T08:46:25-07:00Kết cục điều trị ung thư thanh quản ở bệnh nhân nữ: Phân tích hồi cứu đa trung tâm https://news.medxy.ai/outcomes-of-laryngeal-carcinoma-treatment-in-female-patients-a-multicenter-retrospective-analysis/Medxy AIen2026-09-15T08:46:11-07:00Outcomes of Laryngeal Carcinoma Treatment in Female Patients: A Multicenter Retrospective Analysis https://news.medxy.ai/ja/appendiceal-abscess-diagnosis-2/Medxy AIja2026-09-15T08:45:38-07:00虫垂膿瘍の画像診断と治療経路：2025年イタリア・コンセンサスから読み解く実践ポイント https://news.medxy.ai/vi/appendiceal-abscess-diagnosis/Medxy AIvi2026-09-15T08:45:11-07:00Áp-xe ruột thừa dưới góc nhìn chẩn đoán hình ảnh: cách phân loại và đường đi chẩn đoán từ đồng thuận Ý 2025 https://news.medxy.ai/zh/appendiceal-abscess-imaging/Medxy AIzh2026-09-15T08:44:44-07:00阑尾脓肿的影像分型与诊断路径：2025年意大利共识的临床要点 https://news.medxy.ai/imaging-guided-classification-and-diagnostic-pathways-for-appendiceal-abscesses-practical-takeaways-from-the-2025-italian-consensus/Medxy AIen2026-09-15T08:44:21-07:00Imaging-Guided Classification and Diagnostic Pathways for Appendiceal Abscesses: Practical Takeaways from the 2025 Italian Consensus https://news.medxy.ai/zh/aortic-aneurysm-safety/Medxy AIzh2026-09-15T08:43:24-07:0090岁高龄患者接受血管内主动脉瘤修复术的安全性评估：一项风险校正分析 https://news.medxy.ai/ja/endovascular-aortic-aneurysm-safety/Medxy AIja2026-09-15T08:43:09-07:0090歳以上患者における血管内大動脈瘤修復術の安全性評価：リスク調整解析 https://news.medxy.ai/vi/aortic-aneurysm-repair-safety/Medxy AIvi2026-09-15T08:42:52-07:00Đánh giá độ an toàn của sửa chữa phình động mạch chủ bằng can thiệp nội mạch ở người 90 tuổi trở lên: Phân tích hiệu chỉnh theo nguy cơ https://news.medxy.ai/evaluating-endovascular-aortic-aneurysm-repair-safety-in-nonagenarians-a-risk-adjusted-analysis/Medxy AIen2026-09-15T08:42:35-07:00Evaluating Endovascular Aortic Aneurysm Repair Safety in Nonagenarians: A Risk-Adjusted Analysis https://news.medxy.ai/zh/pancreatic-cancer-5year-survival/Medxy AIzh2026-09-15T08:41:59-07:00局限性胰腺导管腺癌新辅助治疗后手术的真实5年生存结局 https://news.medxy.ai/ja/74099-2/Medxy AIja2026-09-15T08:41:44-07:00局所膵管腺癌に対する術前治療後の手術における実際の5年生存成績 https://news.medxy.ai/vi/survival-5-years/Medxy AIvi2026-09-15T08:41:25-07:00Sống còn thực tế 5 năm sau điều trị tân bổ trợ và phẫu thuật ở ung thư biểu mô tuyến ống tụy khu trú https://news.medxy.ai/real-world-five-year-survival-after-neoadjuvant-therapy-and-surgery-in-localized-pancreatic-ductal-adenocarcinoma/Medxy AIen2026-09-15T08:41:07-07:00Real-World Five-Year Survival After Neoadjuvant Therapy and Surgery in Localized Pancreatic Ductal Adenocarcinoma https://news.medxy.ai/zh/surgical-quality-ratios/Medxy AIzh2026-09-15T08:40:34-07:00重新审视外科质量指标：老年急诊普通外科结局中的手术治疗与非手术治疗比 https://news.medxy.ai/ja/surgical-quality-indicators/Medxy AIja2026-09-15T08:40:19-07:00外科品質指標を再考する：高齢者緊急一般外科転帰における手術的治療／非手術的治療比の意義 https://news.medxy.ai/vi/surgical-quality-measure/Medxy AIvi2026-09-15T08:39:59-07:00Suy nghĩ lại về thước đo chất lượng phẫu thuật: Vai trò của tỷ lệ điều trị phẫu thuật trên điều trị không phẫu thuật trong kết cục phẫu thuật tổng quát cấp cứu ở người cao tuổi https://news.medxy.ai/rethinking-surgical-quality-metrics-the-role-of-operative-to-nonoperative-management-ratio-in-elderly-emergency-general-surgery-outcomes/Medxy AIen2026-09-15T08:39:40-07:00Rethinking Surgical Quality Metrics: The Role of Operative-to-Nonoperative Management Ratio in Elderly Emergency General Surgery Outcomes https://news.medxy.ai/ja/masld-colorectal-cancer-risk-2/Medxy AIja2026-09-15T08:39:03-07:00MASLDで結腸直腸癌リスクは上がるのか？ 国際コンセンサスが示す臨床の要点 https://news.medxy.ai/vi/masld-cancer-risk/Medxy AIvi2026-09-15T08:38:38-07:00Đồng thuận quốc tế mới: nguy cơ ung thư đại trực tràng trong MASLD — bác sĩ lâm sàng cần biết gì https://news.medxy.ai/zh/masld-colorectal-cancer-risk/Medxy AIzh2026-09-15T08:38:14-07:00最新国际共识：MASLD中的结直肠癌风险——临床医生需要了解什么 https://news.medxy.ai/colorectal-cancer-risk/Medxy AIen2026-09-15T08:37:51-07:00New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know https://news.medxy.ai/zh/global-gut-brain-burden/Medxy AIzh2026-09-15T08:36:49-07:00全球肠-脑互动障碍负担：Rome V 与 Rome IV 标准的流行病学对照 https://news.medxy.ai/ja/dgbi-global-burden/Medxy AIja2026-09-15T08:36:32-07:00Rome Vで見えたDGBIの世界的負担：Rome IVとの比較でわかる最新知見 https://news.medxy.ai/vi/global-gut-brain-disorders/Medxy AIvi2026-09-15T08:36:13-07:00Gánh nặng toàn cầu của các rối loạn tương tác ruột–não: So sánh tiêu chuẩn Rome V và Rome IV https://news.medxy.ai/global-burden-of-disorders-of-gut-brain-interaction-insights-from-rome-v-versus-rome-iv-criteria/Medxy AIen2026-09-15T08:35:56-07:00Global Burden of Disorders of Gut-Brain Interaction: Insights from Rome V Versus Rome IV Criteria https://news.medxy.ai/zh/74068-2/Medxy AIzh2026-09-15T08:35:22-07:00远端及中等管径血管闭塞性卒中的早期再通：替奈普酶与阿替普酶的比较 https://news.medxy.ai/ja/early-recanalization/Medxy AIja2026-09-15T08:35:04-07:00遠位・中等大血管閉塞脳梗塞における早期再開通：テネクテプラーゼ vs アルテプラーゼ https://news.medxy.ai/vi/74064-2/Medxy AIvi2026-09-15T08:34:45-07:00Tái thông mạch sớm trong đột quỵ do tắc mạch máu đoạn xa và mạch máu cỡ trung bình: So sánh Tenecteplase và Alteplase https://news.medxy.ai/early-recanalization-in-distal-and-medium-vessel-occlusion-strokes-tenecteplase-vs-alteplase/Medxy AIen2026-09-15T08:34:27-07:00Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs Alteplase https://news.medxy.ai/zh/pediatric-stroke-mri/Medxy AIzh2026-09-15T08:33:49-07:00儿童动脉缺血性卒中中的血管壁MRI：诊断与预后新视角 https://news.medxy.ai/ja/pediatric-arterial-ischemic-stroke-mri/Medxy AIja2026-09-15T08:33:35-07:00小児動脈性虚血性脳卒中における血管壁MRI：診断と予後を読み解く https://news.medxy.ai/vi/mra-stroke-children/Medxy AIvi2026-09-15T08:33:19-07:00Chụp cộng hưởng từ thành mạch trong đột quỵ thiếu máu cục bộ do động mạch ở trẻ em: giá trị chẩn đoán và tiên lượng https://news.medxy.ai/vessel-wall-mri-in-pediatric-arterial-ischemic-stroke-insights-into-diagnosis-and-prognosis/Medxy AIen2026-09-15T08:33:01-07:00Vessel Wall MRI in Pediatric Arterial Ischemic Stroke: Insights into Diagnosis and Prognosis https://news.medxy.ai/zh/levodopa-parkinsons-freezing/Medxy AIzh2026-09-15T08:32:24-07:00重新审视左旋多巴在帕金森病冻结步态中的作用：基于NS-Park与PPMI队列的研究洞见 https://news.medxy.ai/ja/levodopa-parkinson-frozen-steps/Medxy AIja2026-09-15T08:32:08-07:00パーキンソン病のすくみ足におけるレボドパの位置づけを再考する：NS-ParkおよびPPMIコホートからの知見 https://news.medxy.ai/vi/levodopa-freezing-gait-parkinson/Medxy AIvi2026-09-15T08:31:52-07:00Tái đánh giá vai trò của levodopa đối với freezing of gait ở bệnh nhân Parkinson: phân tích từ hai đoàn hệ NS-Park và PPMI https://news.medxy.ai/levodopa-freezing-gait/Medxy AIen2026-09-15T08:31:34-07:00Reevaluating Levodopa’s Role in Freezing of Gait Among Parkinson’s Disease Patients: Insights from NS-Park and PPMI Cohorts https://news.medxy.ai/zh/mri-lacunar-stroke-metrics/Medxy AIzh2026-09-15T08:30:58-07:00MRI确诊腔隙性卒中的代谢特征与因果标志物：来自观察性研究和孟德尔随机化分析的证据 https://news.medxy.ai/ja/mri-lacunar-stroke/Medxy AIja2026-09-15T08:30:42-07:00MRI確認ラクナ脳梗塞における代謝シグネチャーと因果マーカー：観察研究とMendelian randomization解析からの知見 https://news.medxy.ai/vi/74036-2/Medxy AIvi2026-09-15T08:30:23-07:00Dấu ấn chuyển hóa và dấu ấn nhân quả trong nhồi máu não ổ khuyết được xác định bằng MRI https://news.medxy.ai/metabolic-signatures-and-causal-markers-in-mri-confirmed-lacunar-stroke-insights-from-observational-and-mendelian-randomization-analyses/Medxy AIen2026-09-15T08:30:04-07:00Metabolic Signatures and Causal Markers in MRI-Confirmed Lacunar Stroke: Insights from Observational and Mendelian Randomization Analyses https://news.medxy.ai/zh/thalamic-bioenergetics-dpn/Medxy AIzh2026-09-15T08:29:26-07:00疼痛性糖尿病周围神经病变中丘脑生物能量学与神经功能得以保留：来自双模磁共振波谱的启示 https://news.medxy.ai/ja/74030-2/Medxy AIja2026-09-15T08:29:09-07:00疼痛性糖尿病性末梢神経障害における視床の生体エネルギーと神経機能の保持 https://news.medxy.ai/vi/diabetic-peripheral-neuropathy/Medxy AIvi2026-09-15T08:28:49-07:00Đau thần kinh ngoại biên do đái tháo đường: Đồi thị được bảo tồn về chức năng nơron và sinh năng lượng qua MRS kép https://news.medxy.ai/preserved-thalamic-bioenergetics-and-neuronal-function-in-painful-diabetic-peripheral-neuropathy-insights-from-dual-magnetic-resonance-spectroscopy/Medxy AIen2026-09-15T08:28:32-07:00Preserved Thalamic Bioenergetics and Neuronal Function in Painful Diabetic Peripheral Neuropathy: Insights from Dual Magnetic Resonance Spectroscopy https://news.medxy.ai/zh/cortisol-severity-impact/Medxy AIzh2026-09-15T08:27:58-07:00高皮质醇血症严重程度对库欣综合征肾上腺皮质癌结局的影响 https://news.medxy.ai/ja/cushing-syndrome-adrenal-cancer/Medxy AIja2026-09-15T08:27:43-07:00クッシング症候群を伴う副腎皮質癌における高コルチゾール血症の重症度と転帰への影響 https://news.medxy.ai/vi/cortisol-adrenal-cancer/Medxy AIvi2026-09-15T08:27:27-07:00Mức độ tăng cortisol máu ảnh hưởng thế nào đến tiên lượng của u vỏ thượng thận ác tính kèm hội chứng Cushing? https://news.medxy.ai/hypercortisolism-impact/Medxy AIen2026-09-15T08:27:11-07:00Impact of Hypercortisolism Severity on Outcomes in Adrenocortical Carcinoma with Cushing’s Syndrome https://news.medxy.ai/zh/raas-medication-management/Medxy AIzh2026-09-15T08:26:37-07:00原醛症诊断前，RAAS调节药物该停吗？如何在准确性与可行性之间权衡 https://news.medxy.ai/ja/stop-raas-before-aldosteronism/Medxy AIja2026-09-15T08:26:21-07:00原発性アルドステロン症の診断前にRAAS修飾薬は中止すべきか――精度と実用性の両立を考える https://news.medxy.ai/vi/raas-inhibitor-discontinuation/Medxy AIvi2026-09-15T08:26:01-07:00Ngừng thuốc điều biến RAAS trước chẩn đoán cường aldosteron nguyên phát: Cân bằng giữa độ chính xác và tính thực tiễn https://news.medxy.ai/balancing-accuracy-and-practicality-should-raas-modifying-drugs-be-withdrawn-in-primary-aldosteronism-diagnosis/Medxy AIen2026-09-15T08:25:44-07:00Balancing Accuracy and Practicality: Should RAAS-Modifying Drugs Be Withdrawn in Primary Aldosteronism Diagnosis? https://news.medxy.ai/zh/glp-1ra-diabetes-gi-risk/Medxy AIzh2026-09-15T08:25:07-07:00GLP-1RA治疗的2型糖尿病患者：不同阿片类药物的胃肠道风险差异 https://news.medxy.ai/ja/opioid-gut-risk-diabetes/Medxy AIja2026-09-15T08:24:51-07:00GLP-1RA治療中の2型糖尿病患者におけるオピオイドの消化管リスク比較：薬剤別解析 https://news.medxy.ai/vi/opioid-digestive-risk-diabetes/Medxy AIvi2026-09-15T08:24:34-07:00Nguy cơ tiêu hóa khác nhau giữa các opioid ở bệnh nhân đái tháo đường típ 2 đang điều trị GLP-1RA: phân tích so sánh https://news.medxy.ai/differential-gastrointestinal-risks-of-opioids-in-type-2-diabetes-patients-on-glp-1ra-therapy-a-comparative-analysis/Medxy AIen2026-09-15T08:24:18-07:00Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis https://news.medxy.ai/zh/cardiac-resynchronization/Medxy AIzh2026-09-15T08:23:46-07:00心脏再同步化治疗：从代谢组学看心力衰竭的改善机制 https://news.medxy.ai/ja/73992-2/Medxy AIja2026-09-15T08:23:32-07:00心臓再同期療法：メタボロミクスからみた心不全の改善メカニズム https://news.medxy.ai/vi/73990-2/Medxy AIvi2026-09-15T08:23:16-07:00Liệu pháp tái đồng bộ tim: Những hiểu biết từ nghiên cứu chuyển hóa học về sự cải thiện tình trạng suy tim https://news.medxy.ai/cardiac-resynchronization-therapy-metabolomic-insights-into-heart-failure-improvement/Medxy AIen2026-09-15T08:22:58-07:00Cardiac Resynchronization Therapy: Metabolomic Insights into Heart Failure Improvement https://news.medxy.ai/zh/lmna-afib-risk/Medxy AIzh2026-09-15T08:22:26-07:00扩张型心肌病中房颤风险为何因基因而异？——SHaRe Registry 研究揭示 LMNA 突变的关键作用 https://news.medxy.ai/ja/af-risk-genotype/Medxy AIja2026-09-15T08:22:12-07:00拡張型心筋症における心房細動リスクは遺伝子型で異なる：SHaRe Registryからの知見 https://news.medxy.ai/vi/atrial-fibrillation-risk/Medxy AIvi2026-09-15T08:21:55-07:00Nguy cơ và tác động của rung nhĩ ở bệnh cơ tim giãn theo kiểu gen: Phát hiện từ SHaRe Registry https://news.medxy.ai/genotype-dependent-risk-and-impact-of-atrial-fibrillation-in-dilated-cardiomyopathy-insights-from-the-share-registry/Medxy AIen2026-09-15T08:21:38-07:00Genotype-Dependent Risk and Impact of Atrial Fibrillation in Dilated Cardiomyopathy: Insights from the SHaRe Registry https://news.medxy.ai/zh/silent-liver-signals/Medxy AIzh2026-09-15T08:21:06-07:00无声的肝脏信号：亚临床肝病如何推高心血管风险——一项大型前瞻性研究的启示 https://news.medxy.ai/ja/liver-damage-heart-risk/Medxy AIja2026-09-15T08:20:49-07:00見過ごされがちな肝障害が心血管リスクを押し上げる：大規模前向き研究が示す新たな知見 https://news.medxy.ai/vi/subclinical-liver-disease/Medxy AIvi2026-09-15T08:20:32-07:00Bệnh gan dưới lâm sàng: “tác nhân thầm lặng” làm gia tăng nguy cơ tim mạch từ một nghiên cứu tiến cứu quy mô lớn https://news.medxy.ai/subclinical-liver-disease-as-a-silent-driver-of-cardiovascular-risk-insights-from-a-large-scale-prospective-study/Medxy AIen2026-09-15T08:20:16-07:00Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective Study https://news.medxy.ai/zh/night-lighting-effects/Medxy AIzh2026-09-15T08:19:43-07:00夜间灯光并非无害：夜间光暴露如何影响心脏结构、功能及心血管风险 https://news.medxy.ai/ja/night-light-heart-impact/Medxy AIja2026-09-15T08:19:24-07:00夜の光は心臓にどう影響するのか――夜間光暴露が心臓構造・機能と心血管リスクに及ぼす影響 https://news.medxy.ai/vi/73967-2/Medxy AIvi2026-09-15T08:19:04-07:00Ánh sáng ban đêm ảnh hưởng thế nào đến tim? — Tác động của việc tiếp xúc với ánh sáng ban đêm đối với cấu trúc, chức năng tim và nguy cơ tim mạch https://news.medxy.ai/illuminating-the-night-how-nighttime-light-exposure-impacts-cardiac-structure-function-and-cardiovascular-risk/Medxy AIen2026-09-15T08:18:46-07:00Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular Risk https://news.medxy.ai/zh/wildfire-smoke-cardiovascular-risk/Medxy AIzh2026-09-15T07:37:52-07:00长期暴露于野火烟雾 PM2.5：美国老年人心血管风险不容忽视 https://news.medxy.ai/ja/wildfire-smoke-heart-risk/Medxy AIja2026-09-15T07:37:34-07:00米国高齢者における長期的な山火事煙PM2.5曝露がもたらす心血管への負荷 https://news.medxy.ai/vi/pm25-wildfire-exposure/Medxy AIvi2026-09-15T07:37:13-07:00Phơi Nhiễm PM2.5 Từ Khói Cháy Rừng Kéo Dài: Gánh Nặng Tim Mạch Ở Người Cao Tuổi Hoa Kỳ https://news.medxy.ai/unveiling-the-cardiovascular-toll-of-long-term-wildfire-smoke-pm2-5-exposure-in-older-americans/Medxy AIen2026-09-15T07:36:52-07:00Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older Americans https://news.medxy.ai/zh/polygenic-risk-coronary-atherosclerosis/Medxy AIzh2026-09-15T07:36:08-07:00PROACT临床试验中基于多基因风险的亚临床冠状动脉粥样硬化检出与治疗：一种基因型优先的精准预防策略 https://news.medxy.ai/ja/polygenic-risk-detection/Medxy AIja2026-09-15T07:35:47-07:00PROACT試験におけるポリジェニックリスクを基盤とした無症候性冠動脈アテローム性動脈硬化症の検出と治療：genotype-first precision prevention戦略 https://news.medxy.ai/vi/coronary-atherosclerosis-treatment/Medxy AIvi2026-09-15T07:35:24-07:00Phát hiện và điều trị xơ vữa động mạch vành tiền lâm sàng dựa trên nguy cơ đa gen trong các thử nghiệm lâm sàng PROACT: tiếp cận phòng ngừa chính xác theo kiểu genotype-first https://news.medxy.ai/polygenic-risk-based-detection-and-treatment-of-subclinical-coronary-atherosclerosis-in-the-proact-clinical-trials-a-genotype-first-precision-prevention-approach/Medxy AIen2026-09-15T07:35:03-07:00Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention Approach